Abstract
* Raxibacumab is the first monoclonal antibody approved for the treatment and (in some cases) prevention of inhalational anthrax. * Data on the efficacy of raxibacumab are limited and were obtained from animal studies. Human safety trials found that infusion reactions are possible. Other adverse effects weren't serious.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
